Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend [Yahoo! Finance]
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag [Yahoo! Finance]